Description

Book Synopsis


Table of Contents
Section 1: Parkinson’s Disease: Introductory Chapters 1. A Short History of Parkinson’s Disease – from early 19th century and afterwards – an overview2. Living with Parkinson’s disease – from financial to emotional3. The epidemiology of Parkinson’s disease – an overview4. Clinical Features of Parkinson’s disease – an overview5. The natural history of Parkinson’s disease – an overview6. The prognosis of Parkinson’s disease – an overview7. The neurobiology of Parkinson’s disease – an overview8. The pathophysiology of Parkinson’s disease – an overview9. Molecular and cellular mechanisms associated with Parkinson’s disease – synuclein, amyloid protein, oligomers and beyond10. Quality of life in Parkinson’s disease11. Gait in untreated Parkinson’s disease12. Levodopa-induced dyskinesias13. Tremor in Parkinson’s disease14 The impact of Parkinson’s disease on the family and careers Section 2: Biomarkers and Diagnosis15. Tissue biopsies as biomarkers in Parkinson’s disease16. Spinal fluid for biomarker discovery in Parkinson’s disease17. Clinical biomarkers in prodromal Parkinson’s disease18. The diagnosis of Parkinson's disease19. Proteomics in Parkinson’s disease20. MicroRNAs as biomarkers in Parkinson’s diseases21. Phenotyping in Parkinson’s disease22. Diagnosis of speech disorders in Parkinson’s disease23. Identifying dementia in Parkinson’s disease 24. Diagnosis of sleep disturbances in Parkinson’s disease25. Diagnosis of Parkinson’s disease using magnetic resonance imaging26. Use of ultrasound as a diagnostic tool in Parkinson’s disease27. Use of single-photon emission computerized tomography (SPECT) as a diagnostic tool in Parkinson’s disease28. Use of positron emission tomography (PET) as a diagnostic tool in Parkinson’s disease Section 3: Pharmacological Treatments for Parkinson’s Disease29. Dopamine Agonists and Parkinson’s disease – an overview30. Management with Levodopa in Parkinson’s disease31. Management with ripinirole in Parkinson’s disease32. Management with pramipexole in Parkinson’s disease33. Management with rotigotine in Parkinson’s disease34. Management with apomorphine in Parkinson’s disease35. Management with MAO-B Inhibitors in Parkinson’s disease36. Management with COMT inhibitors in Parkinson’s disease37. Management with anticholinergics in Parkinson’s disease38. Management with amantadine in Parkinson’s disease Section 4: Novel and Non-Pharmacological Therapies For Parkinson’s Disease39. Treatment with chelator in Parkinson’s disease40. Treatment with deep brain stimulation in Parkinson’s disease41. Olive leaf extract usage as an antioxidant and applications to Parkinson’s disease42. Treatment with Vitamin D for Parkinson’s disease43. Chemogenetics and applications for Parkinson’s disease44. Flavonoids and naringin usage in Parkinson’s disease45. Stem cells and applications to Parkinson’s disease46. Treatment with cannabis for Parkinson’s disease47. Treating sleep problems in Parkinson’s disease48. Perioperative treatments of Parkinson’s disease49. Exercise and Parkinson’s disease50. Molecular aspects: CB2 receptors and neuroprotection in Parkinson’s disease

Diagnosis and Management in Parkinsons Disease

Product form

£133.45

Includes FREE delivery

RRP £157.00 – you save £23.55 (15%)

Order before 4pm tomorrow for delivery by Tue 23 Dec 2025.

A Hardback by Colin R Martin, Victor R Preedy

7 in stock


    View other formats and editions of Diagnosis and Management in Parkinsons Disease by Colin R Martin

    Publisher: Elsevier Science Publishing Co Inc
    Publication Date: 30/10/2020
    ISBN13: 9780128159460, 978-0128159460
    ISBN10: 0128159464
    Also in:
    Physiology Science & Nature Neurosciences

    Description

    Book Synopsis


    Table of Contents
    Section 1: Parkinson’s Disease: Introductory Chapters 1. A Short History of Parkinson’s Disease – from early 19th century and afterwards – an overview2. Living with Parkinson’s disease – from financial to emotional3. The epidemiology of Parkinson’s disease – an overview4. Clinical Features of Parkinson’s disease – an overview5. The natural history of Parkinson’s disease – an overview6. The prognosis of Parkinson’s disease – an overview7. The neurobiology of Parkinson’s disease – an overview8. The pathophysiology of Parkinson’s disease – an overview9. Molecular and cellular mechanisms associated with Parkinson’s disease – synuclein, amyloid protein, oligomers and beyond10. Quality of life in Parkinson’s disease11. Gait in untreated Parkinson’s disease12. Levodopa-induced dyskinesias13. Tremor in Parkinson’s disease14 The impact of Parkinson’s disease on the family and careers Section 2: Biomarkers and Diagnosis15. Tissue biopsies as biomarkers in Parkinson’s disease16. Spinal fluid for biomarker discovery in Parkinson’s disease17. Clinical biomarkers in prodromal Parkinson’s disease18. The diagnosis of Parkinson's disease19. Proteomics in Parkinson’s disease20. MicroRNAs as biomarkers in Parkinson’s diseases21. Phenotyping in Parkinson’s disease22. Diagnosis of speech disorders in Parkinson’s disease23. Identifying dementia in Parkinson’s disease 24. Diagnosis of sleep disturbances in Parkinson’s disease25. Diagnosis of Parkinson’s disease using magnetic resonance imaging26. Use of ultrasound as a diagnostic tool in Parkinson’s disease27. Use of single-photon emission computerized tomography (SPECT) as a diagnostic tool in Parkinson’s disease28. Use of positron emission tomography (PET) as a diagnostic tool in Parkinson’s disease Section 3: Pharmacological Treatments for Parkinson’s Disease29. Dopamine Agonists and Parkinson’s disease – an overview30. Management with Levodopa in Parkinson’s disease31. Management with ripinirole in Parkinson’s disease32. Management with pramipexole in Parkinson’s disease33. Management with rotigotine in Parkinson’s disease34. Management with apomorphine in Parkinson’s disease35. Management with MAO-B Inhibitors in Parkinson’s disease36. Management with COMT inhibitors in Parkinson’s disease37. Management with anticholinergics in Parkinson’s disease38. Management with amantadine in Parkinson’s disease Section 4: Novel and Non-Pharmacological Therapies For Parkinson’s Disease39. Treatment with chelator in Parkinson’s disease40. Treatment with deep brain stimulation in Parkinson’s disease41. Olive leaf extract usage as an antioxidant and applications to Parkinson’s disease42. Treatment with Vitamin D for Parkinson’s disease43. Chemogenetics and applications for Parkinson’s disease44. Flavonoids and naringin usage in Parkinson’s disease45. Stem cells and applications to Parkinson’s disease46. Treatment with cannabis for Parkinson’s disease47. Treating sleep problems in Parkinson’s disease48. Perioperative treatments of Parkinson’s disease49. Exercise and Parkinson’s disease50. Molecular aspects: CB2 receptors and neuroprotection in Parkinson’s disease

    Recently viewed products

    © 2025 Book Curl

      • American Express
      • Apple Pay
      • Diners Club
      • Discover
      • Google Pay
      • Maestro
      • Mastercard
      • PayPal
      • Shop Pay
      • Union Pay
      • Visa

      Login

      Forgot your password?

      Don't have an account yet?
      Create account